313 related articles for article (PubMed ID: 37131217)
61. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I; Afkhami M; Yang D; Gu Z; Mokhtari S; Shahani S; Pourhassan H; Agrawal V; Koller P; Arslan S; Tomasian V; Al Malki MM; Artz A; Salhotra A; Ali H; Aribi A; Sandhu KS; Ball B; Otoukesh S; Amanam I; Becker PS; Stewart FM; Curtin P; Smith E; Telatar M; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Am J Hematol; 2023 Jun; 98(6):848-856. PubMed ID: 36880203
[TBL] [Abstract][Full Text] [Related]
62. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report.
Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796
[TBL] [Abstract][Full Text] [Related]
63. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
64. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
[TBL] [Abstract][Full Text] [Related]
65. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Agrawal V; Pourhassan H; Tsai NC; Ngo D; Koller P; Malki MMA; Salhotra A; Ali H; Aribi A; Sandhu KS; Arslan S; Ball B; Otoukesh S; Amanam I; Artz A; Singh D; Becker PS; Stewart FM; Smith EP; Curtin P; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V; Aldoss I
Transplant Cell Ther; 2023 May; 29(5):314-320. PubMed ID: 36682470
[TBL] [Abstract][Full Text] [Related]
66. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and
Kayser S; Sartor C; Luskin MR; Webster J; Giglio F; Panitz N; Brunner AM; Fante M; Lutz C; Wolff D; Ho AD; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2022 Sep; 107(9):2064-2071. PubMed ID: 35142153
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
68. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
[TBL] [Abstract][Full Text] [Related]
69. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS
Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361
[TBL] [Abstract][Full Text] [Related]
70. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
[TBL] [Abstract][Full Text] [Related]
71. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Stelljes M; Advani AS; DeAngelo DJ; Wang T; Neuhof A; Vandendries E; Kantarjian H; Jabbour E
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e836-e843. PubMed ID: 35643855
[TBL] [Abstract][Full Text] [Related]
72. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
Cao HY; Wan CL; Xue SL
Ann Hematol; 2023 Jan; 102(1):155-165. PubMed ID: 36394582
[TBL] [Abstract][Full Text] [Related]
73. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation.
Sayyed A; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I
Transplant Cell Ther; 2024 May; 30(5):520.e1-520.e12. PubMed ID: 38462215
[TBL] [Abstract][Full Text] [Related]
74. Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.
Ochs MA; Marini BL; Benitez LL; Stump SE; Weis TM; Buhlinger KM; Diaz T; Reid JH; Muluneh B; Pettit K; Burke P; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2022 Aug; 63(8):1839-1848. PubMed ID: 35345967
[TBL] [Abstract][Full Text] [Related]
75. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
76. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
[TBL] [Abstract][Full Text] [Related]
77. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
78. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
79. Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
Shah B; Chen JMH; Wu JJ; Feng C; Zhou L; Park JE; Hadjiivassileva T; Kerbauy FR; Wade SW; Keeping S
Adv Ther; 2023 Dec; 40(12):5383-5398. PubMed ID: 37801234
[TBL] [Abstract][Full Text] [Related]
80. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
